Pharmaceutical company Siga receives requests for smallpox drug in Europe as monkeypox spreads
Siga Technologies has received requests to use its smallpox drug to treat monkeypox, its chief executive told Reuters on Thursday (May 19th) as cases spread in parts of Europe.
There hadn’t been any deliveries yet but the company was “well positioned” in terms of supply, CEO Phil Gomez said.
The drug, approved to treat smallpox in the US and the orthopoxvirus family that includes monkeypox and cowpox in the EU, has been stockpiled by the government as part of the pandemic response.
“As you can imagine with the outbreak in Europe, we have received requests and are responding to them as we can. We have engaged with our colleagues in Europe on how best to support this response,” Gomez said. , without disclosing details. on requests.
Cases of monkeypox have now been reported or are suspected in Britain, Portugal, Spain and the United States. The virus causes symptoms of fever as well as a characteristic bumpy rash.
The disease, first identified in monkeys, is usually spread by close contact and occurs mainly in West and Central Africa.
Shares of New York-based Siga rose 19% on Thursday, along with shares of other vaccine and smallpox drug developers.
Copenhagen-based drugmaker Bavarian Nordic said on Thursday it had secured a contract with an undisclosed European country to supply its smallpox vaccine, Imvanex, in response to the outbreak.